Equities Analysts Offer Predictions for TYRA FY2026 Earnings

Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) - Equities researchers at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Tyra Biosciences in a research report issued to clients and investors on Monday, May 19th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings of ($2.66) per share for the year. HC Wainwright currently has a "Buy" rating and a $30.00 target price on the stock. The consensus estimate for Tyra Biosciences' current full-year earnings is ($1.57) per share.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02.

Separately, Wedbush reaffirmed an "outperform" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research report on Friday, March 28th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $30.83.

Tyra Biosciences Stock Down 3.1%

Shares of NASDAQ:TYRA opened at $9.68 on Tuesday. The company has a market cap of $513.91 million, a P/E ratio of -6.01 and a beta of 1.17. Tyra Biosciences has a 52 week low of $6.42 and a 52 week high of $29.60. The business has a fifty day simple moving average of $9.53 and a 200-day simple moving average of $12.76.

Institutional Investors Weigh In On Tyra Biosciences

Institutional investors have recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS purchased a new stake in Tyra Biosciences during the fourth quarter valued at about $31,000. US Bancorp DE purchased a new stake in Tyra Biosciences during the fourth quarter valued at about $50,000. BNP Paribas Financial Markets purchased a new stake in Tyra Biosciences during the fourth quarter valued at about $60,000. Aquatic Capital Management LLC purchased a new stake in Tyra Biosciences during the fourth quarter valued at about $64,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Tyra Biosciences during the first quarter valued at about $84,000. Hedge funds and other institutional investors own 84.14% of the company's stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.